CURX
Curanex Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$0.28
+0.01 (+2.99%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.70M | 1.62M | 1.35M |
| Net Income | 499.2K | 484.2K | 288.0K |
| EPS | — | — | — |
| Profit Margin | 29.3% | 29.9% | 21.3% |
| Rev Growth | +22.0% | +2.7% | +4.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.41M | 1.11M | 1.11M |
| Total Equity | 6.14M | 5.98M | 6.63M |
| D/E Ratio | 0.23 | 0.19 | 0.17 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 775.5K | 724.0K | 543.0K |
| Free Cash Flow | 289.5K | 292.3K | 286.4K |